Michelle Doig
Partner, Head of Corporate Development at Omega Funds
Toronto, Ontario
Overview
Work Experience
Board Observer
2024 - Current
Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.
Raised $313,000,000.00 from F-Prime Capital, Janus Henderson Investors, PremjiInvest, Piper Heartland Healthcare Capital, Bioqube Ventures, Omega Funds, The Rise Fund, Braidwell, RA Capital Management and Eight Roads Ventures.
Board Member
2024
Board Observer
2021
Arrakis Therapeutics is a biopharmaceutical developing drugs for neurological disorders and other diseases.
Raised $113,000,000.00 from WuXi AppTec, venBio Partners, OUP (Osage University Partners), Alexandria Venture Investments, Henri Termeer, Omega Funds, Advent Life Sciences, Nextech Invest, Canaan Partners and Celgene.
Board Member
2021
Partner, Head of Corporate Development
2016
Omega Funds global life sciences-based investment firm that specializes in direct secondary transactions.
President and Director
2020
Board Of Directors
2019 - 2021
Nuvation Bio is a global biopharmaceutical company focusing on unmet needs in oncology.
Raised $777,000,000.00 from Boxer Capital, 683 CAPITAL, Ally Bridge Group, Monashee Investment Management, OrbiMed, Irving Investors, Fidelity, Deerfield, Perceptive Advisors and The Baupost Group.
Director, Corporate Finance
2013 - 2016
Principal, Corporate Finance
2004 - 2013
Associate
2001 - 2002